Bioactivation of a Novel 2-Methylindole-Containing Dual Chemoattractant Receptor-Homologous Molecule Expressed on T-Helper Type-2 Cells/d-Prostanoid Receptor Antagonist Leads to Mechanism-Based CYP3A Inactivation: Glutathione Adduct Characterization and Prediction of In Vivo Drug-Drug Interaction

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Drug Metabolism And Disposition

• Publication date

  2010-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.109.031344PMID 20100816
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The roles of the prostaglandin D2 receptors DP1 and CRTH2 in promoting allergic responses

  2008cited by this paper
• Mechanism-Based Inactivation of Lung-Selective Cytochrome P450 CYP2F Enzymes

  2008cited by this paper
• Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: A case study with melanocortin-4 receptor agonists

  2008cited by this paper
• Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions

  2007cited by this paper
• Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.

  2007cited by this paper
• Metabolism and bioactivation of 3-methylindole by human liver microsomes.

  2007cited by this paper
• Comparison of different approaches to predict metabolic drug–drug interactions

  2007influential reference
• Time-dependent CYP inhibition

  2007cited by this paper
• In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance.

  2006cited by this paper
• EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS

  2006influential reference
• Drug-Metabolizing Enzyme Inhibition by Ketoconazole Does Not Reduce Interindividual Variability of CYP3A Activity as Measured by Oral Midazolam

  2006influential reference
• PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION

  2006cited by this paper
• Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

  2005cited by this paper
• Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme.

  2005cited by this paper
• Zafirlukast Metabolism by Cytochrome P450 3A4 Produces an Electrophilic α,β-Unsaturated Iminium Species That Results in the Selective Mechanism-Based Inactivation of the Enzyme

  2005cited by this paper
• A semi-automated method for measuring the potential for protein covalent binding in drug discovery.

  2005cited by this paper
• Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.

  2004cited by this paper
• Validated assays for human cytochrome P450 activities.

  2004cited by this paper
• Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.

  2002cited by this paper
• Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes

  2002cited by this paper
• Bioactivation of toxicants by cytochrome p450-mediated dehydrogenation mechanisms.

  2001cited by this paper
• An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

  2000cited by this paper
• Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction .

  1999influential reference
• Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).

  1999influential reference
• Evidence supporting the formation of 2,3-epoxy-3-methylindoline: a reactive intermediate of the pneumotoxin 3-methylindole.

  1998cited by this paper
• Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.

  1997influential reference
• Mechanistic studies on the cytochrome P450-catalyzed dehydrogenation of 3-methylindole.

  1996cited by this paper
• Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

  1996influential reference
• Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism

  1996influential reference
• Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor.

  1995influential reference
• Mechanism of 3-(glutathion-S-yl)-benzidine formation.

  1994cited by this paper
• Mass spectrometry in the analysis of glutathione conjugates.

  1993cited by this paper
• 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats.

  1992cited by this paper
• Mechanism of formation and structural characterization of DNA adducts derived from peroxidative activation of benzidine.

  1988cited by this paper
• Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture.

  1986influential reference
• Kinetics of suicide substrates. Practical procedures for determining parameters.

  1985cited by this paper
• Mechanism-based enzyme inactivators.

  1984influential reference
• Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450.

  1981cited by this paper
• Kinetics of suicide substrates.

  1980cited by this paper
• Subcellular fractionation of rat liver.

  1974cited by this paper
• [2] Subcellular fractionation of rat liver

  1974cited by this paper

• Pharmacokinetic Drug-Drug Interactions: A Systematic Review of the Cytochrome P450 (CYP) Isoenzyme 3A4

  2023cites this paper
• 1,4,7-Triazacyclononane Restores the Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing Enterobacteriaceae: Exploration of Potential Metallo-β-Lactamase Inhibitors

  2018cites this paper
• TACN (1, 4, 7-Triazacyclononane) restores the activity of β-lactam antibiotics against Metallo-β-Lactamase producing Enterobacteriaceae: The exploration of potential Metallo-β-Lactamase inhibitors

  2018cites this paper
• Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic

  2017cites this paper
• Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors.

  2015cites this paper
• Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP.

  2014cites this paper
• For a series of methylindole analogs, reactive metabolite formation is a poor predictor of intrinsic cytotoxicity in human hepatocytes

  2014cites this paper
• Quantitative Biochemistry in the Pharmacological Evaluation of Drugs

  2013cites this paper
• Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism.

  2013cites this paper
• Pathways of Reactive Metabolite Formation with Toxicophores/‐Structural Alerts

  2012cites this paper
• A Pragmatic Approach Using First-Principle Methods to Address Site of Metabolism with Implications for Reactive Metabolite Formation

  2012cites this paper
• Bioactivation I: Bioactivation by Cytochrome P450s

  2012cites this paper
• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  2012cites this paper
• Prediction of drug-drug interactions arising from mechanism-based inactivation: key input parameters and impact on risk assessment.

  2011cites this paper
• Novel CRTH2 antagonists: a review of patents from 2006 to 2009

  2010cites this paper